Protease inhibitor resistance update: Where are we now?

AIDS Patient Care and STDs

Volumn 22, Issue 4, 2008, Pages 267-277

  Kim, Rose ^a   Baxter, John D ^a  

^a Department of Anesthesiology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR PHOSPHATE; ATAZANAVIR; DARUNAVIR; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TIPRANAVIR;

CLINICAL PRACTICE; CROSS RESISTANCE; DISEASE COURSE; DRUG RESISTANCE; DRUG SENSITIVITY; GENE MUTATION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PROTEASE INHIBITOR RESISTANCE; REVIEW; VIRUS REPLICATION;

AMINO ACID SUBSTITUTION; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUTATION; TREATMENT FAILURE;

EID: 42449133243     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2007.0099     Document Type: Review

References (71)

1. Lehrman G, Hogue IB, Palmer S, et al. Depletion of latent HIV-1 infection in vivo: A proof-of-concept study. Lancet 2005;366:549-555.
2. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006;296:827-843.
3. Panel on Clinical Practices for the Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. U S Department of Health and Human Services October 10, 2006 update. Available at: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL. pdf (Last accessed March 28, 2007).
4. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-860.
5. Murphy EL, Collier AC, Kalish LA, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001;135:17-26.
6. Jacobson MA, French M. Altered natural history of AIDS-related opportunistic infections in the era of potent combination antiretroviral therapy. AIDS 1998;12(suppl A):S157-S163.
7. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med 2004;350:1023-1035.
8. De Mendoza C, Soriano V. Resistance to HIV protease inhibitors: Mechanisms and clinical consequences. Curr Drug Metab 2004;5:321-328.
9. Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001;344:472-480.
10. Kozal M. Cross-resistance patterns among HIV protease inhibitors. AIDS Patient Care STDs 2004;18:199-208.
11. Schnell T, Schmidt B, Moschik G, et al. Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir, and atazanavir in a panel of clinical samples. AIDS 2003;17:1258-1261.
12. Turner D, Schapiro JM, Brenner BG, Wainberg MA. The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients. Antivir Ther 2004;9:301-314.
13. Baxter JD. The experts speak: New issues in the challenge of HIV drug resistance. Interview by Vicki Glaser. AIDS Patient Care STDs 2006;20:737-740.
14. Gilliam BL, Chan-Tack KM, Qaqish RB, et al. Successful treatment with atazanavir and lopinavir/ ritonavir combination therapy in protease inhibitor-susceptible and protease inhibitor-resistant HIV-infected patients. AIDS Patient Care STDs 2006;20:745-759.
15. Gathe JC Jr, Ive P, Wood R, et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS 2004;18:1529-1537.
16. Kempf DJ, King MS, Bernstein B, et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis 2004;189:51-60.
17. Daar ES, Richman DD. Confronting the emergence of drug-resistant HIV type 1: Impact of antiretroviral therapy on individual and population resistance. AIDS Res Hum Retroviruses 2005;21:343-357.
18. Hirsch MS, Brun-Vézinet F, D'Aquila RT, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA Panel. JAMA 2000;283:2417-2426.
19. Little SJ, Holte S, Routy J-P, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002;347:385-394.
20. Pillay D. Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe. Antivir Ther 2004;9:695-702.
21. Deeks SG. Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet 2003;362:2002-2011.
22. Phillips AN, Dunn D, Sabin C, et al. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS 2005;19:487-494.
23. Novak RM, Chen L, MacArthur RD, et al. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: Implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis 2005;40:468-474.
24. Johnson VA, Brun-Vézinet F, Clotet B, et al. Update of the Drug Resistance Mutations in HIV-1: Fall 2006. Top HIV Med 2006;14:125-130.
25. Rhee SY, Liu T, Ravela J, Gonzales MJ, Shafer RW. Distribution of human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns in 4,183 persons undergoing genotypic resistance testing. Antimicrob Agents Chemother 2004;48:3122-3126.
26. Rhee SY, Fessel WJ, Zolopa AR, et al. HIV-1 protease and reverse-transcriptase mutations: Correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. J Infect Dis 2005;192:456-465.
27. Svicher V, Ceccherini-Silberstein F, Erba F, et al. Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors. Antimicrob Agents Chemother 2005;49:2015-2025.
28. Watkins T, Resch W, Irlbeck D, Swanstrom R. Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother 2003;47:759-769.
29. Winters MA, Merigan TC. Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: Clinical impact and molecular mechanisms. Antimicrob Agents Chemother 2005;49:2575-2582.
30. Boden D, Markowitz M. Resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother 1998;42:2775-2783.
31. Gatanaga H, Suzuki Y, Tsang H, et al. Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors. J Biol Chem 2002;277:5952-5961.
32. Mammano F, Trouplin V, Zennou V, Clavel F. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: Virus fitness in the absence and in the presence of drug. J Virol 2000;74:8524-8531.
33. Myint L, Matsuda M, Matsuda Z, et al. Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004;48:444-452.
34. Tamiya S, Mardy S, Kavlick MF, Yoshimura K, Mistuya H. Amino acid insertions near Gag cleavage sites restore the otherwise compromised replication of human immunodeficiency virus type 1 variants resistant to protease inhibitors. J Virol 2004;78:12030-12040.
35. Nijhuis M, van Maarseveen NM, Schipper P, et al. Novel HIV drug resistance mechanism leading to protease inhibitor (PI) resistance in response to a high genetic barrier PI in vitro [abstract 36]. Antivir Ther 2004;9:S42.
36. Miller V. International perspectives on antiretroviral resistance: Resistance to protease inhibitors. J Acquir Immune Defic Syndr 2001;26(suppl 1):S34-S50.
37. Mo H, King MS, King K, et al. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: Mutation patterns and baseline correlates. J Virol 2005;79:3329-3338.
38. Colonno RJ, Thiry A, Limoli K, Parkin N. Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors. Antimicrob Agents Chemother 2003;47:1324-1333.
39. Kempf DJ, Isaacson JD, King MS, et al. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol 2001;75:7462-7469.
40. Svedhem V, Lindkvist A, Bergroth T, Knut L, Sonnerborg A. Diverse pattern of protease inhibitor resistance mutations in HIV-1 infected patients failing nelfinavir. J Med Virol 2005;76:447-451.
41. Chapman TM, Plosker GL, Perry CM. Fosamprenavir: A review of its use in the management of antiretroviral therapy-naive patients with HIV infection. Drugs 2004;64:2101-2124.
42. Rodriguez-French A, Boghossian J, Gray GE, et al. The NEAT study: A 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. J Acquir Immune Defic Syndr 2004;35:22-32.
43. Parkin NT, Chappey C, Petropoulos CJ. Improving lopinavir genotype algorithm through phenotype correlations: Novel mutation patterns and amprenavir cross-resistance. AIDS 2003;17:955-961.
44. Marcelin AG, Cohen-Codar I, King MS, et al. Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients. Antimicrob Agents Chemother 2005;49:1720-1726.
45. Kagan RM, Shenderovich MD, Ramnarayan K, et al. Emergence of a novel lopinavir resistance mutation at codon 47 correlates with ARV utilization. Antivir Ther 2003;8:S54.
46. Parkin NT, Petropoulos CJ, Chappey C, et al. Isolated lopinavir resistance after virological rebound of a lopinavir/ritonavir-based regimen. Antivir Ther 2004;9:S79.
47. Busti AJ, Hall RG II, Margolis DM. Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy 2004;24:1732-1747.
48. Colonno R, Rose R, McLaren C, et al. Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. J Infect Dis 2004;189:1802-1810.
49. Colonno R, Parkin N, McLaren C, et al. Pathways to atazanavir resistance in treatment-experienced patients and impact of residue 50 substitutions [abstract 656]. In: Program and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA: February 8-11, 2004.
50. Coakley E, Mass M, Parkin N. Atazanavir resistance in a protease inhibitor-naïve patient treated with atazanavir/ritonavir associated with development of high-level atazanavir resistance and the N88S mutation in protease [abstract 716]. In: Program and Abstracts of the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA: February 22-25, 2005.
51. Baxter JD, Schapiro JM, Boucher CA, et al. Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J Virol 2006;80:10794-10801.
52. Croom KF, Keam SJ. Tipranavir: A ritonavir-boosted protease inhibitor. Drugs 2005;65:1669-1677.
53. Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: An analysis of combined data from two randomised open-label trials. Lancet 2006;368:466-475.
54. De Meyer S, Azijn H, Surleraux D, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 2005;49:2314-2321.
55. De Meyer S, Vangeneugden T, Lefebvre E, et al. Phenotypic and genotypic determinants of resistance to TMC114: Pooled analysis of POWER 1, 2, and 3. Antivir Ther 2006;11:S83.
56. Vacca JP, Holloway MK, Allison TJ, et al. Structural basis for the resistance profile of the HIV-1 protease inhibitor PL-100. Antivir Ther 2007;12:S17.
57. Callebaut C, Stray K, Tsai J, et al. In vitro HIV-1 resistance selection to GS-8374, a novel phosphonate protease inhibitor: Comparison with lopinavir, atazanavir and darunavir. Antivir Ther 2007;12:S18.
58. Afonina E, Gulnik SV, Eissenstat M, et al. Highly potent protease inhibitors with novel escape pathways. Antivir Ther 2007;12:S21.
59. Amano M, Koh Y, Das D, et al. A novel bis-tetrahydrofuranylurethane- containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother 2007;51:2143-2155.
60. Winters MA, Baxter JD, Mayers DL, et al. Frequency of antiretroviral drug resistance mutations in HIV-1 strains from patients failing triple drug regimens. Antivir Ther 2000;5:57-63.
61. Hertogs K, Bloor S, Kemp SD, et al. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: A survey of over 6000 samples. AIDS 2000;14:1203-1210.
62. Ziermann R, Limoli K, Das K, et al. A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir. J Virol 2000;74:4414-4419.
63. Schooley R, Haubrich R, Thompson M, et al. Effect of amprenavir hyper-susceptibility on the response to APV/ritonavir-based therapy in ART-experienced adults selected by baseline susceptibility (ESS40006): 24-week data [Abstract 143]. In: Program and Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA: February 10-14, 2003.
64. Colonno R, Rose R, Cianci C, et al. Emergence of atazanavir resistance and maintenance of susceptibility to other PIs is associated with an I50L substitution in HIV protease [abstract 597]. In: Program and Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA: February 10-14, 2003.
65. Menzo S, Monachetti A, Balotta C, et al. Fitness and drug-dependence in HIV-1 variants resistant to protease inhibitors [abstract 618]. In: Program and Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA: February 10-14, 2003.
66. Kozal MJ, Huppler Hullsiek K, Leduc R, et al. Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients. Antivir Ther 2006;11:457-463.
67. Johnston E, Winters MA, Rhee SY, et al. Association of a novel human immunodeficiency virus type 1 protease substrate cleft mutation, L23I, with protease inhibitor therapy and in vitro drug resistance. Antimicrob Agents Chemother 2004;48:4864-4868.
68. Kuritzkes DR. Preventing and managing antiretroviral drug resistance. AIDS Patient Care STDS 2004;18:259-273.
69. Lawrence J, Hullsiek KH, Thackeray LM, et al. Disadvantages of structured treatment interruption persist in patients with multidrug-resistant HIV-1: Final results of the CPCRA 064 study. J Acquir Immune Defic Syndr 2006;43:169-178.
70. Rodes B, Garcia F, Gutierrez C, et al. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral- experienced HIV-infected patients. J Med Virol 2005;77:23-28.
71. Shafer RW, Rhee SY, Pillay D, et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 2007;21:215-223.